Alunbrig 30 mg (Brigatinib TABLET) 30 MG

Alunbrig 30 mg is an oral tablet containing brigatinib, used for targeted therapy. This medication is commonly prescribed for specific cancer treatments and is manufactured by Takeda Canada Inc.

Strength

30 MG

Pack Size

28/30/56//60

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Alunbrig 30 mg is primarily used in the treatment of certain types of cancer. Brigatinib, the active ingredient, is designed to target specific proteins involved in cancer cell growth. Patients often wonder, 'What is Alunbrig used for?' This medication is typically prescribed for advanced or metastatic cancers that have specific genetic markers.

Side Effects

Common effects of Alunbrig 30 mg may include nausea, fatigue, and cough. Some users experience changes in taste or vision. These effects can vary widely among individuals and are not exhaustive. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Alunbrig 30 mg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions. Pregnant women or those planning to become pregnant should discuss the risks with their healthcare provider.

Avoid Interactions

Alunbrig 30 mg may interact with certain medications, including those that affect liver enzymes. Alcohol and other substances that impact liver function should be avoided unless approved by a healthcare provider. Always inform your healthcare provider about all medications you are taking.

Frequently Asked Questions

Alunbrig 30 mg is used in the treatment of certain types of cancer, particularly those with specific genetic markers.

Alunbrig 30 mg is an oral tablet that should be taken as prescribed by a healthcare provider. Follow the dosage and administration instructions carefully.

Common side effects may include nausea, fatigue, and cough. Individual experiences can vary, and not all side effects are listed here.

Alunbrig 30 mg may interact with certain medications. Always inform your healthcare provider about all medications you are taking.

Pregnant women or those planning to become pregnant should discuss the risks with their healthcare provider before taking Alunbrig 30 mg.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.